Compare AstraZeneca plc (AZN) vs Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? AstraZeneca plc trades at $168.85 (market cap $253.13B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $29.05. The key difference: AstraZeneca plc pays a 1.92% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none, and AstraZeneca plc is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| AZN | RDTE | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $209.48 | $34.72 |
52-Week Low | $137.44 | $26.40 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
RDTE trades at $28.72, down 0.62% today, with technical indicators signaling a bearish trend. The stock shows consistent dividend payments but lacks key valuation metrics like P/E and P/S, limiting fundamental clarity. Recent news highlights structural risks in its covered call strategy, which may erode capital over time despite high yield potential.
Outlook remains cautious due to capital erosion risks from its strategy capping upside. Investment opportunity hinges on yield appeal, but risks include NAV deterioration and inability to capture market rallies. Investors should weigh high income against potential long-term value loss.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →
